Ricardo J Flores1,2,3, Aaron J Kelly1,2,4, Yiting Li1,2, Manjula Nakka1,2, Donald A Barkauskas5,6, Mark Krailo5,6, Lisa L Wang1,2,3, Laszlo Perlaky1,2,3, Ching C Lau1,2,3,4, M John Hicks3,7, Tsz-Kwong Man1,2,3,4. 1. Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas. 2. Department of Pediatrics, Baylor College of Medicine, Houston, Texas. 3. Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas. 4. Program of Structural and Computational Biology and Molecular Biophysics, Baylor College of Medicine, Houston, Texas. 5. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California. 6. Children's Oncology Group, Monrovia, California. 7. Department of Pathology, Baylor College of Medicine, Houston, Texas.
Abstract
BACKGROUND: Osteosarcoma (OS) is the most common malignant pediatric bone tumor. The identification of novel biomarkers for early prognostication will facilitate risk-based stratification and therapy. This study investigated the significance of circulating cytokines/chemokines for predicting the prognosis at the initial diagnosis. METHODS: Luminex assays were used to measure cytokine/chemokine concentrations in blood samples from a discovery cohort of OS patients from Texas Children's Hospital (n = 37) and an independent validation cohort obtained from the Children's Oncology Group (n = 233). After the validation of the biomarkers, a multivariate model was constructed to stratify the patients into risk groups. RESULTS: The circulating concentrations of C-X-C motif chemokine ligand 10 (CXCL10), Fms-related tyrosine kinase 3 ligand (FLT3LG), interferon γ (IFNG), and C-C motif chemokine ligand 4 (CCL4) were significantly associated with overall survival in both cohorts. Among these candidates, CXCL10 and FLT3LG were independent of the existing prognostic factor, metastasis at diagnosis, and CCL4 further discriminated cancer cases from controls. CXCL10, FLT3LG, and the metastatic status at diagnosis were combined to develop a multivariate model that significantly stratified the patients into 4 distinct risk groups (P = 1.6 × 10-8 ). The survival analysis showed that the 5-year overall survival rates for the low-, intermediate-, high-, and very high-risk groups were 77%, 54%, 47%, and 10%, respectively, whereas the 5-year event-free survival rates were 64%, 47%, 27%, and 0%, respectively. Neither CXCL10 nor FLT3LG tumor expression was significantly associated with survival. CONCLUSIONS: High circulating levels of CXCL10 and FLT3LG predicted worse survival for patients with OS. Because both CXCL10 and FL3LG axes are potentially targetable, further study may lead to novel risk-based stratification and therapy for OS. Cancer 2017;144-154.
BACKGROUND:Osteosarcoma (OS) is the most common malignant pediatric bone tumor. The identification of novel biomarkers for early prognostication will facilitate risk-based stratification and therapy. This study investigated the significance of circulating cytokines/chemokines for predicting the prognosis at the initial diagnosis. METHODS: Luminex assays were used to measure cytokine/chemokine concentrations in blood samples from a discovery cohort of OS patients from Texas Children's Hospital (n = 37) and an independent validation cohort obtained from the Children's Oncology Group (n = 233). After the validation of the biomarkers, a multivariate model was constructed to stratify the patients into risk groups. RESULTS: The circulating concentrations of C-X-C motif chemokine ligand 10 (CXCL10), Fms-related tyrosine kinase 3 ligand (FLT3LG), interferon γ (IFNG), and C-C motif chemokine ligand 4 (CCL4) were significantly associated with overall survival in both cohorts. Among these candidates, CXCL10 and FLT3LG were independent of the existing prognostic factor, metastasis at diagnosis, and CCL4 further discriminated cancer cases from controls. CXCL10, FLT3LG, and the metastatic status at diagnosis were combined to develop a multivariate model that significantly stratified the patients into 4 distinct risk groups (P = 1.6 × 10-8 ). The survival analysis showed that the 5-year overall survival rates for the low-, intermediate-, high-, and very high-risk groups were 77%, 54%, 47%, and 10%, respectively, whereas the 5-year event-free survival rates were 64%, 47%, 27%, and 0%, respectively. Neither CXCL10 nor FLT3LGtumor expression was significantly associated with survival. CONCLUSIONS: High circulating levels of CXCL10 and FLT3LG predicted worse survival for patients with OS. Because both CXCL10 and FL3LG axes are potentially targetable, further study may lead to novel risk-based stratification and therapy for OS. Cancer 2017;144-154.
Authors: Jan Smida; Daniel Baumhoer; Michael Rosemann; Axel Walch; Stefan Bielack; Christopher Poremba; Klaus Remberger; Eberhard Korsching; Wolfram Scheurlen; Christian Dierkes; Stefan Burdach; Gernot Jundt; Michael J Atkinson; Michaela Nathrath Journal: Clin Cancer Res Date: 2010-07-07 Impact factor: 12.531
Authors: S Bielack; B Kempf-Bielack; D Schwenzer; T Birkfellner; G Delling; V Ewerbeck; G U Exner; N Fuchs; U Göbel; N Graf; U Heise; K Helmke; A R von Hochstetter; H Jürgens; R Maas; N Münchow; M Salzer-Kuntschik; J Treuner; U Veltmann; M Werner; W Winkelmann; A Zoubek; R Kotz Journal: Klin Padiatr Date: 1999 Jul-Aug Impact factor: 1.349
Authors: Ricardo J Flores; Aaron J Kelly; Yiting Li; Xiang Chen; Colin McGee; Mark Krailo; Donald A Barkauskas; John Hicks; Tsz-Kwong Man Journal: Pediatr Blood Cancer Date: 2017-05-24 Impact factor: 3.167
Authors: Troy A McEachron; Timothy J Triche; Laurie Sorenson; David M Parham; John D Carpten Journal: Oncoimmunology Date: 2018-09-11 Impact factor: 8.110
Authors: Thomas Gp Grünewald; Marta Alonso; Sofia Avnet; Ana Banito; Stefan Burdach; Florencia Cidre-Aranaz; Gemma Di Pompo; Martin Distel; Heathcliff Dorado-Garcia; Javier Garcia-Castro; Laura González-González; Agamemnon E Grigoriadis; Merve Kasan; Christian Koelsche; Manuela Krumbholz; Fernando Lecanda; Silvia Lemma; Dario L Longo; Claudia Madrigal-Esquivel; Álvaro Morales-Molina; Julian Musa; Shunya Ohmura; Benjamin Ory; Miguel Pereira-Silva; Francesca Perut; Rene Rodriguez; Carolin Seeling; Nada Al Shaaili; Shabnam Shaabani; Kristina Shiavone; Snehadri Sinha; Eleni M Tomazou; Marcel Trautmann; Maria Vela; Yvonne Mh Versleijen-Jonkers; Julia Visgauss; Marta Zalacain; Sebastian J Schober; Andrej Lissat; William R English; Nicola Baldini; Dominique Heymann Journal: EMBO Mol Med Date: 2020-10-13 Impact factor: 12.137